gemcitabine has been researched along with Fatigue in 55 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (3.64) | 18.2507 |
| 2000's | 14 (25.45) | 29.6817 |
| 2010's | 35 (63.64) | 24.3611 |
| 2020's | 4 (7.27) | 2.80 |
| Authors | Studies |
|---|---|
| Bowering, V; Chang, K; Dhani, NC; Karakasis, K; Kavak, N; Lheureux, S; Madariaga, A; Mitchell, SA; Oza, AM; Pittman, T; Quintos, J; Ramsahai, J; Wang, L; Welch, SA | 1 |
| Du, S; Fan, L; Li, Y; Liu, Y; Wang, J | 1 |
| Bendell, J; Greil, R; Gueorguieva, I; Hecht, JR; Hozak, RR; Lin, Y; Lonardi, S; Lopez, CD; Macarulla, T; Muñoz Martin, AJ; Park, JO; Rao, S; Ryoo, BY; Sim, HW; Van Cutsem, E; Wang, H | 1 |
| Abou-Alfa, GK; Bekaii-Saab, TS; Bitzer, M; Borad, MJ; Borbath, I; El-Khoueiry, A; Goyal, L; Javle, M; Kelley, RK; Li, A; Macarulla, T; Moran, S; Pande, A; Philip, PA; Roychowdhury, S; Sadeghi, S; Shepherd, SP; Soifer, HS; Tanasanvimon, S; Waldschmidt, DT; Weiss, KH; Yong, WP; Zhu, AX | 1 |
| Ahn, JS; Awada, A; Cortés, J; Diéras, V; Gómez-Pardo, P; Hannah, AL; Hoch, U; Im, SA; Mailliez, A; Moreno-Aspitia, A; O'Shaughnessy, J; Perez, EA; Potter, DA; Rugo, HS; Schwartzberg, LS; Tagliaferri, M; Twelves, C; Yardley, DA; Zhao, C | 1 |
| Blaydorn, L; Coats, J; Farley, JH; Khemka, V; Lynch, CA; McGahey, K; Niu, J; Sangal, A; Waypa, J; Weiss, GJ | 1 |
| Crane, CH; Cuaron, JJ; Goodman, KA; Hajj, C; Lowery, MA; O'Reilly, EM; Park, JJ; Reyngold, M; Shi, W; Wu, AJ; Yu, KH; Zhang, Z | 1 |
| Arkenau, HT; Blackhall, F; Califano, R; Dean, E; Dymond, AW; Ghiorghiu, D; Greystoke, A; Hossack, S; Lindsay, CR; Md Haris, N; Plummer, R; So, K; Steele, N; Summers, Y; Voskoboynik, M | 1 |
| Bjerregaard, JK; Ejlsmark, MW; Jensen, HA; Krogh, M; Pfeiffer, P; Schonnemann, KR; Winther, SB | 1 |
| Blackwood, EM; Cousin, S; DuPree, K; Epler, J; Hamilton, E; Hollebecque, A; Infante, JR; Italiano, A; Lauchle, JO; LoRusso, PM; Lu, X; Mahrus, S; Moein, A; Moore, KN; Murray, ER; Peale, FV; Postel-Vinay, S; Schutzman, JL; Shapiro, GI; Soria, JC; Tagen, M; Tolaney, S; Toulmonde, M | 1 |
| Abe, M; Chiba, T; Iino, Y; Kato, N; Mikata, R; Ogawa, Y; Ohyama, H; Suzuki, E; Tsuyuguchi, T; Yasui, S | 1 |
| Fløtten, Ø; Grønberg, BH; Kristensen, A; Solheim, TS | 1 |
| Ahmed, S; Chalchal, H; Haider, K; Moser, M; Olson, C; Papneja, N; Shaw, J; Tan, K; Zaidi, A | 1 |
| Diaz, CL; Hwang, J; Johns, C; Kerridge, WD; Ko, AH; Tempero, MA | 1 |
| Bekaii-Saab, TS; Chidiac, TA; Criswell, T; Fernandez, SA; Guttridge, D; Villalona-Calero, M; Wu, C | 1 |
| Beck, JT; Bell-McGuinn, K; Eisenberg, P; Emanuelson, R; Hermann, RC; Hudis, CA; Isaacs, C; Kaklamani, V; Keaton, M; Kirshner, JJ; Levine, E; Lokker, NA; Makari-Judson, G; Medgyesy, DC; Qamar, R; Ro, SK; Rugo, HS; Schwartzberg, LS; Starr, A; Stepanski, EJ; Tauer, KW; Wang, W | 1 |
| Jarboe, J; Saif, MW | 1 |
| Cataruozolo, PE; Cesari, R; Collier, M; Cortés, J; Curigliano, G; Elias, A; Goldhirsch, A; Huang, X; Kern, KA; Khosravan, R; Pivot, X | 1 |
| Budai, B; Ganofszky, E; Hitre, E; Horváth, Z; Juhos, E; Láng, I; Nagy, T; Rubovszky, G; Szabó, E; Szentirmay, Z | 1 |
| Hamada, T; Hirano, K; Ijichi, H; Isayama, H; Ishigami, H; Kawakubo, K; Kitayama, J; Kogure, H; Koike, K; Miyabayashi, K; Mizuno, S; Mohri, D; Nakai, Y; Sasahira, N; Sasaki, T; Tada, M; Takahara, N; Tateishi, K; Uchino, R; Watanabe, T; Yamaguchi, H; Yamamoto, N; Yamashita, H | 1 |
| Anthoney, A; Archer, C; Corrie, P; Costello, E; Cox, T; Coxon, F; Cunningham, D; Eatock, M; Evans, J; Falk, S; Garcia-Alonso, A; Greenhalf, W; Harrison, M; Hickish, T; Iveson, T; Madhusudan, S; McAdam, K; Middleton, G; Naisbitt, D; Nanson, G; Neoptolemos, J; Nicolson, M; Propper, D; Rawcliffe, C; Robinson, A; Roques, T; Ross, P; Shaw, V; Silcocks, P; Steward, W; Valle, J; Wadd, N; Wadsley, J | 1 |
| Liljefors, M; Rossmann, E; Ullenhag, GJ | 1 |
| Beijnen, JH; Boss, DS; Grob, M; Huitema, AD; Keessen, M; Rehorst, H; Rosing, H; Schellens, JH; Smit, WM; Tibben, MM; van der Noll, R; Wymenga, AN | 1 |
| Abrams, RA; Blazeby, JM; Bridges, S; Bridgewater, J; Crosby, T; Dutton, P; Falk, S; Griffiths, G; Hurt, CN; Johnson, C; Joseph, G; Maughan, T; McDonald, A; Mukherjee, S; Staffurth, J | 1 |
| Bayever, E; Belanger, B; Blanc, JF; Bodoky, G; Braiteh, F; Chen, LT; Chiu, CF; Cunningham, D; Dean, A; Dhindsa, N; Hubner, RA; Jameson, G; Lee, KH; Li, CP; Macarulla, T; Moyo, V; Schwartsmann, G; Shan, YS; Siveke, JT; Von Hoff, DD; Wang-Gillam, A | 1 |
| Adam, J; Bastien, B; Beck, JT; Chouaid, C; Debieuvre, D; Felip, E; Forget, F; Gervais, R; Halluard, C; Kazarnowicz, A; Lacoste, G; Lena, H; Limacher, JM; Losonczy, G; Madroszyk, A; Ottensmeier, C; Palanché, T; Papai, Z; Quoix, E; Szczesna, A; Tavernaro, A; Westeel, V | 1 |
| Becerra, C; Bence Lin, A; Braiteh, F; Calvo, E; Galsky, MD; Hurt, K; Hynes, SM; Jameson, G; Lin, J; McKane, S; McWilliams, R; Richards, D; Von Hoff, D; Wickremsinhe, ER | 1 |
| Altundag, K; Barnadas, A; Botha, M; Chan, A; Cinieri, S; Coskun, U; Dodyk, P; Lazzarelli, S; Rauch, D; Tubiana-Mathieu, N; Vandebroek, A; Villanova, G | 1 |
| Alexandrescu, DT; Dasanu, CA; Herzog, TJ | 1 |
| Bang, YJ; Cha, Y; Choi, IK; Choi, IS; Kim, CD; Kim, JH; Kim, JS; Kim, YH; Oh, DY; Oh, SC; Yoon, SY | 1 |
| Canil, C; Dent, SF; Gertler, S; Goel, R; Iscoe, N; Keller, O; Segal, R; Verma, S; Young, V | 1 |
| Benda, J; Boardman, CH; Cella, D; Cohn, DE; McMeekin, DS; Monk, BJ; Ramondetta, LM; Sill, MW | 1 |
| Azria, D; Budach, V; Collette, L; Hammel, P; Haustermans, K; Lutz, M; Mauer, M; Mornex, F; Peeters, M; Polus, M; Praet, M; Van Cutsem, E; Van Laethem, JL; Van Tienhoven, G; Vergauwe, P | 1 |
| Boni, L; Caffo, O; de Marinis, F; Dondi, D; Ferraù, F; Galligioni, E; Gamucci, T; Gebbia, V; Grossi, F; Moscetti, L; Nardi, M; Riccardi, F | 1 |
| Ball, D; Burmeister, BH; Burmeister, E; Cox, S; Forouzesh, B; Horwood, K; Lehman, M; Michael, M; Sasso, G; Wirth, A | 1 |
| Burris, HA; Ervin, TJ; Greco, FA; Hainsworth, JD; Kohler, PC; Lubiner, ET; Peyton, JD; Shipley, DL; Spigel, DR; Waterhouse, DM | 1 |
| Adjei, AA; Dy, GK; Eckhardt, SG; Jimeno, A; Ma, WW; Maniar, M; Messersmith, WA; Ren, C; Weekes, CD; Whitworth, A; Wilhelm, F | 1 |
| He, AN; Qi, WX; Shen, Z; Tang, LN; Yao, Y | 1 |
| Adjei, AA; Ansari, RH; Dy, GK; Lyss, AP; Mandrekar, SJ; Meyers, JP; Molina, JR; Nelson, GD; Ross, HJ; Schild, SE; Stella, PJ | 1 |
| Apolo, AB; Bajorin, DF; Balar, AV; Gallagher, DJ; Garcia-Grossman, IR; Iasonos, A; Milowsky, MI; Mironov, S; Ostrovnaya, I; Regazzi, AM; Trout, A | 1 |
| Colowick, AB; Fleishman, A; Glaspy, JA; Jadeja, JS; Justice, G; Rossi, G | 1 |
| Daugherty, CK; Huo, D; Janisch, L; Larson, RA; Odenike, OM; Ratain, MJ; Sobecks, RM; Zimmerman, TM | 1 |
| Furuse, J; Hasegawa, R; Ikeda, M; Ishii, H; Kaniwa, N; Kikura-Hanajiri, R; Kim, SR; Okusaka, T; Ozawa, S; Saijo, N; Saito, Y; Sawada, J; Sugiyama, E; Ueno, H; Yamamoto, N; Yonemori, K; Yoshida, T | 1 |
| Bearden, JD; Blackstock, AW; Butler, J; Case, LD; Ennever, PR; Ho, C; Howerton, R; Levine, E; Magrinat, GC; Melin, S; Minotto, DC; Mishra, G | 1 |
| Cao, CW; Gao, Y; Guo, J; Shi, ZQ; Zhu, CL | 1 |
| Bai, LY; Chen, PM; Poh, SB | 1 |
| Chen, YM; Perng, RP; Tsai, CM; Whang-Peng, J | 1 |
| Basche, M; Chow, LQ; Eckhardt, SG; Gore, L; Grolnic, S; Morrow, M; O'Bryant, CL; Schultz, MK | 1 |
| Bruntsch, U; Catimel, G; Clavel, M; de Mulder, P; Judson, I; Piccart, M; Sessa, C; Vermorken, JB; Verweij, J; Wanders, J | 1 |
| Fukuoka, M; Furue, H; Furuse, K; Majima, H; Morimoto, K; Nakamura, T; Nakao, I; Niitani, H; Ohta, K; Shimoyama, T; Taguchi, T; Tsukagoshi, S; Wakui, A | 1 |
| Barth, RJ; Colacchio, TA; Lewis, LD; McDonnell, C; Meyer, LP; Mitchell, SE; Perez, RP; Pipas, JM; Rathmann, J; Vera-Gimon, R; Wagman, RS | 1 |
| Abbruzzese, JL; Charnsangavej, C; Evans, DB; Gravel, DM; Janjan, NA; Lee, JE; Lenzi, R; Pisters, PW; Wolff, RA | 1 |
| Bertucci, D; Mani, S; Ratain, MJ; Schilsky, RL; Stadler, WM; Vogelzang, NJ | 1 |
| Depisch, D; Haider, K; Kornek, GV; Kovats, E; Kwasny, W; Lang, F; Payrits, T; Raderer, M; Scheithauer, W; Schüll, B | 1 |
| Ikeda, M; Okada, S; Okusaka, T; Tokuuye, K; Ueno, H | 1 |
2 review(s) available for gemcitabine and Fatigue
| Article | Year |
|---|---|
Associations between hematologic toxicity and health-related quality of life during first-line chemotherapy in advanced non-small-cell lung cancer: a pooled analysis of two randomized trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Deoxycytidine; Fatigue; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Quality of Life; Randomized Controlled Trials as Topic; Vinorelbine | 2018 |
Comparison between doublet agents versus single agent in metastatic breast cancer patients previously treated with an anthracycline and a taxane: a meta-analysis of four phase III trials.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Diarrhea; Disease-Free Survival; Fatigue; Female; Fluorouracil; Gemcitabine; Hand-Foot Syndrome; Humans; Middle Aged; Nausea; Neutropenia; Salvage Therapy; Stomatitis; Survival Analysis; Taxoids; Thrombocytopenia; Vomiting; Young Adult | 2013 |
45 trial(s) available for gemcitabine and Fatigue
| Article | Year |
|---|---|
Patient self-reporting of tolerability using PRO-CTCAE in a randomized double-blind, placebo-controlled phase II trial comparing gemcitabine in combination with adavosertib or placebo in patients with platinum resistant or refractory epithelial ovarian ca
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Double-Blind Method; Fatigue; Female; Gemcitabine; Humans; Ovarian Neoplasms; Platinum | 2022 |
Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Interleukin-10; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Outcome Assessment, Health Care; Oxaliplatin; Pancreatic Neoplasms; Polyethylene Glycols; Thrombocytopenia | 2021 |
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Central Serous Chorioretinopathy; Cholangiocarcinoma; Deoxycytidine; Disease Progression; Dry Eye Syndromes; Fatigue; Female; Gemcitabine; Humans; Hyperphosphatemia; Male; Middle Aged; Neoplasm Metastasis; Phenylurea Compounds; Pyrimidines; Radiation-Sensitizing Agents; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Fibroblast Growth Factor, Type 2; Retinal Detachment; Safety; Stomatitis; Treatment Outcome | 2021 |
Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Albumins; Anorexia; Antineoplastic Agents; Body Image; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Cancer Pain; Deoxycytidine; Docetaxel; Dyspnea; Epothilones; Fatigue; Female; Furans; Gemcitabine; Health Status; Heterocyclic Compounds, 4 or More Rings; Humans; Ketones; Liver Neoplasms; Lung Neoplasms; Middle Aged; Nausea; Paclitaxel; Polyethylene Glycols; Quality of Life; Reproductive Health; Sleep Initiation and Maintenance Disorders; Taxoids; Vinblastine; Vinorelbine; Vomiting | 2017 |
A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diarrhea; Docetaxel; Doxorubicin; Drug Eruptions; Fatigue; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasms; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols; Sarcoma; Small Cell Lung Carcinoma; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Vomiting | 2017 |
SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy-Induced Febrile Neutropenia; Cisplatin; Deoxycytidine; Diarrhea; Epistaxis; Fatigue; Female; Gemcitabine; Humans; Lethargy; Lung Neoplasms; Male; Middle Aged; Nausea; Pemetrexed; Protein Kinase Inhibitors; Thrombocytopenia; Vomiting | 2017 |
Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Checkpoint Kinase 1; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Fatigue; Female; Gemcitabine; Half-Life; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasms; Neutropenia; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Thrombocytopenia; Treatment Outcome | 2018 |
Disrupting cytokine signaling in pancreatic cancer: a phase I/II study of etanercept in combination with gemcitabine in patients with advanced disease.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cytokines; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Etanercept; Fatigue; Female; Gemcitabine; Humans; Immunoglobulin G; Interferon-gamma; Interleukin-10; Interleukin-1beta; Interleukin-6; Male; Middle Aged; Nausea; Pancreatic Neoplasms; Receptors, Tumor Necrosis Factor; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Treatment Outcome; Tumor Necrosis Factor-alpha | 2013 |
Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Niacinamide; Phenylurea Compounds; Receptor, ErbB-2; Skin Diseases; Sorafenib; Stomatitis; Treatment Outcome | 2013 |
Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Docetaxel; Fatigue; Female; Fluorouracil; Gemcitabine; Hand-Foot Syndrome; Humans; Indoles; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Pyrroles; Sunitinib; Survival Rate; Taxoids; Thrombocytopenia; Triple Negative Breast Neoplasms | 2013 |
Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study.
Topics: Adult; Aged; Anemia; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Cetuximab; Deoxycytidine; DNA Mutational Analysis; Drug Administration Schedule; Exanthema; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Regression Analysis; Treatment Outcome | 2013 |
Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis.
Topics: Adenocarcinoma; Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Ascites; Catheter-Related Infections; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Fatigue; Feasibility Studies; Female; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Infusions, Intravenous; Infusions, Parenteral; Male; Middle Aged; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Salvage Therapy; Tegafur; Treatment Outcome | 2014 |
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Capecitabine; Cell Proliferation; Deoxycytidine; Disease-Free Survival; Fatigue; Female; Fluorouracil; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunologic Factors; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Pain; Pancreatic Ducts; Pancreatic Neoplasms; Peptide Fragments; T-Lymphocytes; Telomerase | 2014 |
A phase I dose-escalation study of lenalidomide in combination with gemcitabine in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Administration, Oral; Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Dalteparin; Deoxycytidine; Drug Administration Schedule; Fatigue; Female; Gemcitabine; Humans; Injections, Intravenous; Lenalidomide; Leukopenia; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Pancreas; Pancreatic Neoplasms; Thalidomide | 2015 |
Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Fatigue; Female; Gemcitabine; Humans; Lapatinib; Middle Aged; Quinazolines | 2015 |
Health-Related Quality of Life in SCALOP, a Randomized Phase 2 Trial Comparing Chemoradiation Therapy Regimens in Locally Advanced Pancreatic Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Drug Administration Schedule; Fatigue; Feeding and Eating Disorders; Female; Follow-Up Studies; Gastrointestinal Diseases; Gemcitabine; Health Status; Humans; Induction Chemotherapy; Male; Pancreatic Neoplasms; Quality of Life; Statistics, Nonparametric; Surveys and Questionnaires; United Kingdom | 2015 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Diarrhea; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Liposomes; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pancreatic Neoplasms; Treatment Outcome; Vomiting | 2016 |
TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.
Topics: Aged; Anemia; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Cancer Vaccines; Carboplatin; Carcinoma, Non-Small-Cell Lung; CD56 Antigen; Cisplatin; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Erlotinib Hydrochloride; Fatigue; Female; Gemcitabine; Humans; Immunotherapy; Lectins, C-Type; Lung Neoplasms; Lymphocyte Activation; Lymphocytes; Male; Membrane Glycoproteins; Middle Aged; Mucin-1; Neutropenia; Paclitaxel; Pemetrexed; Predictive Value of Tests; Receptors, IgG | 2016 |
Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid Tumors.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Checkpoint Kinase 1; Deoxycytidine; Fatigue; Female; Gemcitabine; Half-Life; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Phenylurea Compounds; Pyrazines; Thrombocytopenia; Young Adult | 2016 |
Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Fatigue; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Quality of Life; Receptor, ErbB-2; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2017 |
A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Fatigue; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Nausea; Neutropenia; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Treatment Outcome | 2010 |
A phase II study of biweekly pemetrexed and gemcitabine in patients with metastatic breast cancer.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Drug Administration Schedule; Exanthema; Fatigue; Female; Gemcitabine; Glutamates; Guanine; Humans; Middle Aged; Neoplasm Metastasis; Pemetrexed; Pneumonia; Treatment Outcome | 2010 |
Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Fatigue; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Paclitaxel; Prognosis; Quality of Life; Topotecan; Treatment Outcome; Uterine Cervical Neoplasms; Vinblastine; Vinorelbine; Young Adult | 2009 |
Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Diarrhea; Drug Administration Schedule; Fatigue; Feasibility Studies; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nausea; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Treatment Outcome | 2010 |
A randomised phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Fatigue; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Taxoids; Treatment Outcome | 2012 |
A randomized phase II trial of two regimens of moderate dose chemoradiation therapy for patients with non-small cell lung cancer not suitable for curative therapy: Trans Tasman Radiation Oncology Study TROG 03.07.
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Deoxycytidine; Disease-Free Survival; Dose Fractionation, Radiation; Dyspnea; Fatigue; Feasibility Studies; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Proportional Hazards Models; Quality of Life; Treatment Outcome; Vinblastine; Vinorelbine | 2011 |
A randomized phase II trial of pemetrexed/gemcitabine/bevacizumab or pemetrexed/carboplatin/bevacizumab in the first-line treatment of elderly patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Fatigue; Female; Gemcitabine; Glutamates; Guanine; Humans; Infections; Kaplan-Meier Estimate; Lung Neoplasms; Male; Neutropenia; Pemetrexed; Thrombocytopenia; Thromboembolism; Time Factors; Treatment Outcome | 2012 |
Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cell Cycle Proteins; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Follow-Up Studies; Gemcitabine; Glycine; Humans; Lymphopenia; Male; Middle Aged; Neoplasms; Neutropenia; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinase; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Signal Transduction; Sulfones; Survival Analysis; Treatment Outcome | 2012 |
A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: North Central Cancer Treatment Group Study N0528.
Topics: Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Dyspnea; Fatigue; Female; Gemcitabine; Humans; Hypothyroidism; Kaplan-Meier Estimate; Logistic Models; Lung Neoplasms; Male; Middle Aged; Neutropenia; Polymorphism, Single Nucleotide; Proportional Hazards Models; Quinazolines; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Fibroblast Growth Factor, Type 2; Stomatitis; Vascular Endothelial Growth Factor Receptor-3 | 2013 |
Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Constipation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Treatment Outcome; Urologic Neoplasms; Urothelium | 2013 |
A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Darbepoetin alfa; Deoxycytidine; Docetaxel; Erythropoietin; Fatigue; Female; Gemcitabine; Humans; Injections, Subcutaneous; Male; Middle Aged; Neoplasms; Paclitaxel; Pilot Projects; Taxoids; Treatment Outcome | 2003 |
A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant diseases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Deoxycytidine; Drug Administration Schedule; Fatigue; Feasibility Studies; Female; Gemcitabine; Hematologic Neoplasms; Humans; Male; Middle Aged; Neutropenia; Thrombocytopenia | 2004 |
Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin.
Topics: Aged; Amino Acid Substitution; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cisplatin; Cytidine Deaminase; Deoxycytidine; DNA Mutational Analysis; DNA, Neoplasm; Exanthema; Fatigue; Floxuridine; Gemcitabine; Genotype; Humans; Japan; Male; Middle Aged; Neoplasms; Neutropenia; Polymorphism, Single Nucleotide; Stomatitis; Thrombocytopenia; Treatment Outcome | 2005 |
Phase II trial of induction gemcitabine/CPT-11 followed by a twice-weekly infusion of gemcitabine and concurrent external beam radiation for the treatment of locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Diarrhea; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Gastrointestinal Diseases; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Nausea; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Survival Rate; Thrombocytopenia; Vomiting | 2005 |
[A randomized trial of docetaxol plus cisplatin versus gemzar plus cisplatin in treating advanced non-small cell lung cancer].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Fatigue; Female; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Remission Induction; Survival Rate; Taxoids; Thrombocytopenia | 2005 |
Pegylated liposomal doxorubicin-based combination chemotherapy as salvage treatment in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; alpha-Fetoproteins; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Doxorubicin; Fatigue; Female; Fluorouracil; Gemcitabine; Hepatitis B, Chronic; Humans; Liposomes; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Mucositis; Neoplasm Proteins; Paresthesia; Polyethylene Glycols; Salvage Therapy; Survival Analysis; Treatment Outcome | 2005 |
A phase II trial of gemcitabine plus UFUR combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Erlotinib Hydrochloride; Fatigue; Female; Gefitinib; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Salvage Therapy; Survival Rate; Tegafur | 2006 |
A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Farnesyltranstransferase; Fatigue; Female; Gemcitabine; HSP40 Heat-Shock Proteins; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Piperidines; Pyridines; Treatment Outcome; Vomiting | 2008 |
A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group.
Topics: Adult; Aged; Alanine Transaminase; Antimetabolites, Antineoplastic; Aspartate Aminotransferases; Carcinoma, Squamous Cell; Deoxycytidine; Europe; Fatigue; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Liver; Male; Middle Aged; Neutropenia; Remission Induction | 1994 |
[LY188011 phase I study. Research Group of Gemcitabine (LY188011)].
Topics: Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Bone Marrow; Deoxycytidine; Drug Administration Schedule; Fatigue; Female; Fever; Gastrointestinal Neoplasms; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Nausea; Vomiting | 1996 |
Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Bone Marrow Diseases; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Gemcitabine; Humans; Male; Middle Aged; Nausea; Pancreatectomy; Pancreatic Neoplasms; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, High-Energy; Remission Induction; Survival Analysis; Treatment Outcome | 2001 |
Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Fatigue; Female; Gemcitabine; Humans; Male; Middle Aged; Nausea; Pancreatic Neoplasms; Treatment Outcome; Vomiting | 2001 |
Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
Topics: Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Renal Cell; Deoxycytidine; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasms; Neutropenia; Treatment Outcome | 2001 |
Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factor.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Fatigue; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Leukopenia; Middle Aged; Nausea; Nervous System Diseases; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
A phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with locally advanced pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-19-9 Antigen; Chemical and Drug Induced Liver Injury; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Gemcitabine; Humans; Leukopenia; Male; Maximum Tolerated Dose; Middle Aged; Palliative Care; Pancreatic Neoplasms; Radiotherapy, High-Energy; Treatment Outcome | 2002 |
8 other study(ies) available for gemcitabine and Fatigue
| Article | Year |
|---|---|
Clinical Study of Anti-PD-1 Immunotherapy Combined with Gemcitabine Chemotherapy in Multiline Treatment of Advanced Pancreatic Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Carcinoembryonic Antigen; Deoxycytidine; Fatigue; Gemcitabine; Humans; Immunotherapy; Pancreatic Neoplasms; Retrospective Studies | 2022 |
Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Deoxycytidine; Diarrhea; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Mucositis; Multivariate Analysis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Proportional Hazards Models; Radiation Injuries; Radiosurgery; Radiotherapy, Intensity-Modulated; Retrospective Studies; Survival Rate; Thrombocytopenia | 2017 |
S-1 (Teysuno) and gemcitabine in Caucasian patients with unresectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Diarrhea; Drug Combinations; Fatigue; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Treatment Outcome; White People | 2018 |
Five Cases of Interstitial Pneumonitis Due to Gemcitabine and Nab-Paclitaxel Combination Treatment in Pancreatic Cancer Patients.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fatigue; Female; Gemcitabine; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Neutropenia; Paclitaxel; Pancreatic Neoplasms | 2018 |
Comparisons of Outcomes of Real-World Patients With Advanced Pancreatic Cancer Treated With FOLFIRINOX Versus Gemcitabine and Nab-Paclitaxel: A Population-Based Cohort Study.
Topics: Aged; Albumins; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Community Health Planning; Deoxycytidine; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Nausea; Outcome Assessment, Health Care; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Proportional Hazards Models; Saskatchewan | 2019 |
Alternate Week Gemcitabine and Capecitabine: An Effective Treatment for Patients With Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administration Schedule; Fatigue; Female; Gemcitabine; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2019 |
First line therapy for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Administration Schedule; Fatigue; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2013 |
Carboplatin-gemcitabine in the therapy of advanced ovarian cancer: dose reduction consideration.
Topics: Adenocarcinoma; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Deoxycytidine; Epistaxis; Fatigue; Female; Gemcitabine; Humans; Leukopenia; Liver Neoplasms; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Pelvic Neoplasms; Remission Induction; Splenic Neoplasms; Thrombocytopenia | 2010 |